SG11201809310PA - Isoquinolin-3-yl carboxamides and preparation and use thereof - Google Patents

Isoquinolin-3-yl carboxamides and preparation and use thereof

Info

Publication number
SG11201809310PA
SG11201809310PA SG11201809310PA SG11201809310PA SG11201809310PA SG 11201809310P A SG11201809310P A SG 11201809310PA SG 11201809310P A SG11201809310P A SG 11201809310PA SG 11201809310P A SG11201809310P A SG 11201809310PA SG 11201809310P A SG11201809310P A SG 11201809310PA
Authority
SG
Singapore
Prior art keywords
san diego
international
california
street
pct
Prior art date
Application number
SG11201809310PA
Inventor
Sunil Kumar Kc
Gopi Kumar Mittapalli
Brian Joseph Hofilena
Joseph Timothy Marakovits
Chandramouli Chiruta
Chi Ching Mak
Jianguo Cao
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of SG11201809310PA publication Critical patent/SG11201809310PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 November 2017 (02.11.2017) WIP0 I PCT omit VIII VIII lII 0 HE Eloilloo 111E1111°111 (10) International Publication Number WO 2017/189823 A3 (51) International Patent Classification: CO7D 217/22 (2006.01) A61K 31/4725 (2006.01) A61K 31/472 (2006.01) CO7D 217/12 (2006.01) (21) International Application Number: PCT/US2017/029797 (22) International Filing Date: 27 April 2017 (27.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/328,210 27 April 2016 (27.04.2016) US (71) Applicant: SAMUMED, LLC [US/US]; 9381 Judicial Drive, Suite 160, San Diego, California 92121 (US). (72) Inventors: KC, Sunil Kumar; 10504 Clasico Court, San Diego, California 92127 (US). MITTAPALLI, Gopi Ku- mar; 4158 Decoro Street #47, San Diego, California 92122 (US). HOFILENA, Brian Joseph; 4049 Florida Street, #1, San Diego, California 92104 (US). MARAKOVITS, Joseph Timothy; 2403 Summerhill Drive, Encinitas, Cal- ifornia 92024 (US). CHIRUTA, Chandramouli; 4158 Decoro Street, Apt. 61, San Diego, California 92122 (US). MAK, Chi Ching; 12057 World Trade Drive, Unit 3, San Diego, Arizona 92128 (US). CAO, Jianguo; 9898 Avenger Court, San Diego, California 92126 (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 08 February 2018 (08.02.2018) W O 20 17 / 1898 23 A3 (74) Agent: DORIGO, Andrea et al.; Fish & Richardson P.C., PO Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (54) Title: ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF (57) : Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
SG11201809310PA 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof SG11201809310PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328210P 2016-04-27 2016-04-27
PCT/US2017/029797 WO2017189823A2 (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Publications (1)

Publication Number Publication Date
SG11201809310PA true SG11201809310PA (en) 2018-11-29

Family

ID=60157342

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201914127PA SG10201914127PA (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof
SG11201809310PA SG11201809310PA (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201914127PA SG10201914127PA (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Country Status (19)

Country Link
US (5) US10508099B2 (en)
EP (2) EP3448838B1 (en)
JP (1) JP7023243B2 (en)
KR (1) KR102399206B1 (en)
CN (1) CN109311819B (en)
AR (1) AR108326A1 (en)
AU (1) AU2017258187B2 (en)
BR (1) BR112018072190A2 (en)
CA (1) CA3022044A1 (en)
CL (2) CL2018003050A1 (en)
CO (1) CO2018012655A2 (en)
IL (1) IL262495B (en)
MA (1) MA43605B1 (en)
MX (1) MX2018013173A (en)
PE (1) PE20190260A1 (en)
PH (1) PH12018502259A1 (en)
RU (1) RU2018141379A (en)
SG (2) SG10201914127PA (en)
WO (1) WO2017189823A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2935222T (en) 2012-12-21 2018-12-10 Epizyme Inc Prmt5 inhibitors and uses thereof
TW201803869A (en) 2016-04-27 2018-02-01 健生藥品公司 6-aminopyridin-3-yl thiazoles as modulators of ROR[gamma]t
AR108326A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
AR108325A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
US20180282282A1 (en) 2017-03-30 2018-10-04 Genentech, Inc. Isoquinolines as inhibitors of hpk1
JP2020537667A (en) * 2017-10-17 2020-12-24 ヴァンダービルト ユニバーシティー Antagonist of muscarinic acetylcholine receptor M4
WO2019079626A1 (en) * 2017-10-19 2019-04-25 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
WO2019084496A1 (en) 2017-10-27 2019-05-02 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
CA3103929A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
CN112334450A (en) 2018-06-18 2021-02-05 詹森药业有限公司 Phenyl and pyridyl substituted imidazoles as modulators of ROR γ t
CN112292373A (en) 2018-06-18 2021-01-29 詹森药业有限公司 Pyridylpyrazoles as modulators of ROR γ t
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
TW202024053A (en) 2018-10-02 2020-07-01 美商建南德克公司 Isoquinoline compounds and uses thereof
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
MX2022002720A (en) * 2019-09-05 2022-08-10 Lunan Pharmaceutical Group Corp Magl inhibitor, preparation method therefor and use thereof.
US20230406844A1 (en) * 2020-10-29 2023-12-21 Merck Sharp & Dohme Llc N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
CA3211159A1 (en) * 2021-02-19 2022-08-25 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
WO2023055679A1 (en) * 2021-10-01 2023-04-06 Merck Sharp & Dohme Llc C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2023107714A2 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2131463B1 (en) * 1997-04-08 2000-03-01 Lilly Sa DERIVATIVES OF CYCLOPROPYLGLYCIN WITH PHARMACEUTICAL PROPERTIES.
DE19746287A1 (en) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (en) 1998-11-19 2003-04-03 Thomas Lenarz Catheter for the application of medication in fluid spaces of the human inner ear
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (en) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20060264897A1 (en) 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2007125405A2 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
CA2696321A1 (en) * 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
SI2464232T1 (en) * 2009-08-10 2016-03-31 Samumed, Llc. Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CA2770320A1 (en) 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
EP2552893B1 (en) * 2010-03-31 2014-10-29 Actelion Pharmaceuticals Ltd. Antibacterial isoquinolin-3-ylurea derivatives
BR112013013790A2 (en) 2010-12-17 2016-09-13 Hoffmann La Roche substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
CN103929963A (en) 2011-09-14 2014-07-16 萨穆梅德有限公司 Indazole-3-carboxamides and their use as WNT/beta-CATENIN signaling pathway inhibitors
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
SG10201914111XA (en) 2014-03-20 2020-03-30 Samumed Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108326A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
AR108325A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
US20220062240A1 (en) 2018-06-26 2022-03-03 Biosplice Therapeutics, Inc. Methods of treating cancer using a clk inhibitor

Also Published As

Publication number Publication date
EP3448838B1 (en) 2021-08-11
CN109311819B (en) 2022-10-25
US10287267B2 (en) 2019-05-14
EP3448838A4 (en) 2019-12-25
US11174244B2 (en) 2021-11-16
PH12018502259A1 (en) 2019-06-10
MA43605A1 (en) 2020-04-30
SG10201914127PA (en) 2020-02-27
CA3022044A1 (en) 2017-11-02
WO2017189823A3 (en) 2018-02-08
MX2018013173A (en) 2019-02-13
KR102399206B1 (en) 2022-05-17
PE20190260A1 (en) 2019-02-25
JP2019515931A (en) 2019-06-13
US10556885B2 (en) 2020-02-11
US20180208580A1 (en) 2018-07-26
IL262495B (en) 2021-12-01
EP3943086A1 (en) 2022-01-26
IL262495A (en) 2018-12-31
CL2018003050A1 (en) 2019-01-25
CO2018012655A2 (en) 2019-04-30
AR108326A1 (en) 2018-08-08
EP3448838A2 (en) 2019-03-06
MA43605B1 (en) 2020-10-28
US11673881B2 (en) 2023-06-13
RU2018141379A3 (en) 2020-08-13
JP7023243B2 (en) 2022-02-21
CL2019002067A1 (en) 2020-07-10
US20200339536A1 (en) 2020-10-29
US10508099B2 (en) 2019-12-17
US20230104155A1 (en) 2023-04-06
KR20190012167A (en) 2019-02-08
BR112018072190A2 (en) 2019-02-12
AU2017258187B2 (en) 2021-08-26
AU2017258187A1 (en) 2018-11-15
WO2017189823A2 (en) 2017-11-02
CN109311819A (en) 2019-02-05
US20170313681A1 (en) 2017-11-02
US20180222887A1 (en) 2018-08-09
RU2018141379A (en) 2020-05-28

Similar Documents

Publication Publication Date Title
SG11201809310PA (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
SG11201809301YA (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201809299QA (en) Formulations of an lsd1 inhibitor
SG11201903331QA (en) Restimulation of cryopreserved tumor infiltrating lymphocytes
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201807972YA (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SG11201408261UA (en) Syringe
SG11201804395PA (en) Pharmaceutical compositions comprising levodopa amide and uses thereof
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201809674QA (en) Adenine derivatives as protein kinase inhibitors
SG11201806157WA (en) Method and pharmaceutical composition for treatment of neurodegeneration
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction